Geriatric emergency medication safety recommendations: Difference between revisions
No edit summary |
|||
| (34 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Background== | |||
*Consensus guidelines with alternative medications for geriatric medication use upon discharge from the ED. | |||
===High-Risk Medications to Avoid for Geriatric Patients at ED Discharge<ref>Skains, et al. Geriatric Emergency Medication Safety Recommendations (GEMS-Rx). Annals of Emergency Medicine. September 2024. 84(3):274-284. https://doi.org/10.1016/j.annemergmed.2024.01.033</ref>=== | ===High-Risk Medications to Avoid for Geriatric Patients at ED Discharge<ref>Skains, et al. Geriatric Emergency Medication Safety Recommendations (GEMS-Rx). Annals of Emergency Medicine. September 2024. 84(3):274-284. https://doi.org/10.1016/j.annemergmed.2024.01.033</ref>=== | ||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- | ||
! Therapeutic Class | ! High-Risk Therapeutic Class (AVOID) | ||
! | ! Alternative Options (Preferred) | ||
! | ! Valid Exceptions^ (Use with Caution) | ||
|- | |- | ||
| [[Barbiturates]] | | [[Barbiturates]] | ||
| Line 11: | Line 13: | ||
| | | | ||
*[[Epilepsy]] | *[[Epilepsy]] | ||
**Use other anticonvulsants | **Use other [[anticonvulsants]] | ||
**Examples: [[lamotrigine]], [[levetiracetam]]) | |||
*[[Agitation]] | *[[Agitation]] | ||
**Treat pain first with [[acetaminophen]] then low-dose [[opioid]] | **Treat pain first with [[acetaminophen]] then low-dose [[opioid]] | ||
*Severe [[agitation]] | *Severe [[agitation]] | ||
**Use low-dose second-generation antipsychotic | **Use low-dose second-generation antipsychotic | ||
| | **Examples: [[olanzapine]], [[risperidone]], [[quetiapine]] (Lewy body dementia) | ||
*[[ | | | ||
*[[Seizure disorders]] | |||
**[[Benzodiazepine withdrawal]] | |||
**[[Ethanol withdrawal]] | |||
|- | |- | ||
| [[Benzodiazepines]] | | [[Benzodiazepines]] | ||
*Examples: [[diazepam]], [[lorazepam]], [[midazolam]] | *Examples: [[diazepam]], [[lorazepam]], [[midazolam]] | ||
| | | | ||
*Epilepsy | *[[Epilepsy]] | ||
*Agitation | **Use other [[anticonvulsants]] | ||
**Examples: [[lamotrigine]], [[levetiracetam]] | |||
| | *[[Agitation]] | ||
*Seizure disorders | **Treat pain first with [[acetaminophen]] then low-dose [[opioid]] | ||
*Severe [[agitation]] | |||
**use nonpharmacologic approach then low-dose second-generation [[antipsychotic]] | |||
**Examples: [[olanzapine]], [[risperidone]], [[quetiapine]] (Lewy body dementia) | |||
| | |||
*[[Seizure disorders]] | |||
**[[Benzodiazepine withdrawal]] | |||
**[[Ethanol withdrawal]] | |||
**Severe generalized [[anxiety disorder]] | |||
**[[Palliative care]] | |||
|- | |- | ||
| First-generation [[antihistamines]] | | First-generation [[antihistamines]] | ||
*Examples: [[diphenhydramine]] (Benadryl), [[doxylamine]], [[hydroxyzine]] (Vistaril), [[meclizine]] | *Examples: [[diphenhydramine]] (Benadryl), [[doxylamine]], [[hydroxyzine]] (Vistaril), [[meclizine]] | ||
| | | | ||
*Allergies | *[[Allergies]] | ||
*Vertigo | **Use intranasal saline or steroid (e.g., [[fluticasone]], [[beclomethasone]]), topical antihistamines (e.g., [[azelastine]]), or second-generation antihistamines (e.g., [[fexofenadine]], [[loratadine]]). | ||
*[[Vertigo]] | |||
**Use short-term steroids and canalith repositioning maneuvers. | |||
| | | | ||
* | *[[Acute allergic reaction]]s | ||
|- | |- | ||
|[[Metoclopramide]] | |[[Metoclopramide]] | ||
| | | | ||
* | *[[Nausea]] | ||
**Use [[ondansetron]] | |||
| | | | ||
* | *[[Gastroparesis]] | ||
|- | |- | ||
|First-generation [[antipsychotics]] | |First-generation [[antipsychotics]] | ||
*Examples: [[haloperidol]], [[prochlorperazine]], [[promethazine]] | |||
| | | | ||
*Second-generation antipsychotics | *Second-generation antipsychotics | ||
**Examples: [[olanzapine]], [[risperidone]], [[quetiapine]], [[aripiprazole]], [[ziprasidone]] | |||
| | | | ||
|- | |- | ||
|Nonbenzodiazepine | |[[Nonbenzodiazepine]]s (Z-drugs) | ||
*Examples: [[zolpidem]] (Ambien), [[zaleplon]] (Sonata), [[eszopiclone]] (Lunesta) | |||
| | | | ||
*Insomnia | *Insomnia | ||
*Anxiety | **Use [[melatonin]], [[ramelteon]], [[doxepin]] (<=3 mg) | ||
*Anxiety | |||
**Use [[mirtazapine]], [[buspirone]], serotonin–norepinephrine reuptake inhibitor (serotonin and norepinephrine reuptake inhibitor, eg, [[duloxetine]], [[venlafaxine]], [[desvenlafaxine]]) | |||
| | | | ||
|- | |- | ||
|Skeletal muscle relaxants | |[[Skeletal muscle relaxants]] | ||
*Examples: [[Baclofen]] (Lioresal), [[dantrolene]] (Dantrium), [[cyclobenzaprine]] (Amrix) | |||
| | | | ||
*Treat musculoskeletal pain first with nonpharmacologic agents ( | *Treat musculoskeletal pain first with nonpharmacologic agents (e.g., heat, ice, massage) then with [[acetaminophen]], short-course [[NSAIDs]], [[lidocaine]] patch, [[diclofenac]] gel. | ||
| | | | ||
|- | |- | ||
|[[Sulfonylureas]] | |[[Sulfonylureas]] | ||
|Metformin, long-acting insulin ( | *Examples: [[Glipizide]], [[glyburide]] | ||
| | |||
*[[Metformin]], long-acting [[insulin]] (e.g., [[glargine]]) | |||
| | | | ||
|} | |} | ||
^ | ^Indications for use where high-risk medication benefit may outweigh risks. | ||
==See Also== | ==See Also== | ||
*[[Geriatrics (main)]] | *[[Geriatrics (main)]] | ||
==References== | |||
Latest revision as of 23:32, 20 May 2026
Background
- Consensus guidelines with alternative medications for geriatric medication use upon discharge from the ED.
High-Risk Medications to Avoid for Geriatric Patients at ED Discharge[1]
| High-Risk Therapeutic Class (AVOID) | Alternative Options (Preferred) | Valid Exceptions^ (Use with Caution) |
|---|---|---|
Barbiturates
|
|
|
| Benzodiazepines |
|
|
First-generation antihistamines
|
|
|
| Metoclopramide |
|
|
First-generation antipsychotics
|
|
|
Nonbenzodiazepines (Z-drugs)
|
|
|
Skeletal muscle relaxants
|
|
|
| Sulfonylureas |
^Indications for use where high-risk medication benefit may outweigh risks.
See Also
References
- ↑ Skains, et al. Geriatric Emergency Medication Safety Recommendations (GEMS-Rx). Annals of Emergency Medicine. September 2024. 84(3):274-284. https://doi.org/10.1016/j.annemergmed.2024.01.033
